{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:24:17Z","timestamp":1795026257880,"version":"4.10.2"},"reference-count":27,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of excessive and maladaptive inflammation. Primary HLH is most frequently encountered in young children, and, without timely recognition and therapy, can lead to multiorgan failure and death. It is most often diagnosed using the HLH-2004 criteria and by identifying pathological mutations. However, the HLH-2004 criteria are not specific for HLH, and patients can easily fulfill these diagnostic criteria in other proinflammatory states in which HLH-therapy would not be indicated, including hematologic malignancies, infections, and rheumatologic disease. Therefore, great care must be taken to ensure that the specific disease associated with features of HLH is accurately recognized, as consequences of improper treatment can be catastrophic. We propose a diagnostic pathway for patients for whom HLH is on the differential (visual abstract). Importantly, in situations in which the initial diagnostic workup is equivocal or unrevealing, reevaluation for occult malignancy, infection, or rheumatologic disease would be prudent, as occult presentations may be missed on primary evaluation. Temporizing medications can be used in critically ill patients while awaiting secondary evaluation. By using this framework, clinicians will be able to more reliably discern primary HLH from other pro-inflammatory states and thus provide timely, appropriate disease-specific therapy.<\/jats:p>","DOI":"10.1182\/hematology.2023000463","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:09:59Z","timestamp":1702048199000},"page":"31-36","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Inflamed\u2014HLH, MAS, or something else?"],"prefix":"10.1182","volume":"2023","author":[{"given":"Ashish","family":"Kumar","sequence":"first","affiliation":[{"name":"1 Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"},{"name":"2 Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eily","family":"Cournoyer","sequence":"additional","affiliation":[{"name":"1 Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Naymagon","sequence":"additional","affiliation":[{"name":"3 Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"5","key":"2023120815061669100_hem2023000463C1","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003664","article-title":"Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect","volume":"136","author":"Carvelli","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2023120815061669100_hem2023000463C2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/asheducation-2013.1.605","article-title":"Hemophagocytic lymphohistiocytosis: pathogenesis and treatment","volume":"2013","author":"Janka","year":"2013","journal-title":"Hematology"},{"issue":"5446","key":"2023120815061669100_hem2023000463C3","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1126\/science.286.5446.1957","article-title":"Perforin gene defects in familial hemophagocytic lymphohistiocytosis","volume":"286","author":"Stepp","year":"1999","journal-title":"Science"},{"issue":"3","key":"2023120815061669100_hem2023000463C4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1086\/318796","article-title":"Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis","volume":"68","author":"G\u00f6ransdotter Ericson","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2023120815061669100_hem2023000463C5","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.hoc.2015.06.007","article-title":"Pathogenesis of hemophagocytic lymphohistiocytosis","volume":"29","author":"Filipovich","year":"2015","journal-title":"Hematol\/Oncol Clin N Am"},{"issue":"16","key":"2023120815061669100_hem2023000463C6","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1182\/blood.2019000936","article-title":"Pediatric hemophagocytic lymphohistiocytosis","volume":"135","author":"Canna","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2023120815061669100_hem2023000463C7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"25","key":"2023120815061669100_hem2023000463C8","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2023120815061669100_hem2023000463C9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/bjh.14147","article-title":"Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities","volume":"174","author":"Brisse","year":"2016","journal-title":"Br J Haematol"},{"issue":"23","key":"2023120815061669100_hem2023000463C10","doi-asserted-by":"crossref","first-page":"153321","DOI":"10.1016\/j.prp.2020.153321","article-title":"Can we truly diagnose adult secondary hemophagocytic lymphohistiocytosis (HLH)? a critical review of current paradigms","volume":"218","author":"Naymagon","year":"2021","journal-title":"Pathol - Res Pract"},{"issue":"12","key":"2023120815061669100_hem2023000463C11","doi-asserted-by":"crossref","first-page":"e27400","DOI":"10.1002\/pbc.27400","article-title":"Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis","volume":"65","author":"Gurunathan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2023120815061669100_hem2023000463C12","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3389\/fimmu.2019.01740","article-title":"Current flow cytometric assays for the screening and diagnosis of primary HLH","volume":"10","author":"Chiang","year":"2019","journal-title":"Front Immunol"},{"issue":"22","key":"2023120815061669100_hem2023000463C13","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood-2016-12-753830","article-title":"Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH","volume":"129","author":"Rubin","year":"2017","journal-title":"Blood"},{"key":"2023120815061669100_hem2023000463C14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fped.2019.00071","article-title":"Epstein-Barr virus-associated T and NK-cell lymphoproliferative diseases","volume":"7","author":"Kim","year":"2019","journal-title":"Front Pediatr"},{"issue":"1","key":"2023120815061669100_hem2023000463C15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.17638","article-title":"Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes","volume":"196","author":"El-Mallawany","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"2023120815061669100_hem2023000463C16","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.2019000928","article-title":"Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection","volume":"135","author":"Tangye","year":"2020","journal-title":"Blood"},{"key":"2023120815061669100_hem2023000463C17","doi-asserted-by":"crossref","first-page":"981251","DOI":"10.3389\/fimmu.2022.981251","article-title":"Development of a screening score for hemophagocytic lymphohistiocytosis among pediatric patients with acute infection of Epstein-Barr virus","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"2023120815061669100_hem2023000463C18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/bjh.12386","article-title":"Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens","volume":"162","author":"Chellapandian","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2023120815061669100_hem2023000463C19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1159\/000514920","article-title":"The Efficacy of etoposide-based therapy in adult secondary hemophagocytic lymphohistiocytosis","volume":"144","author":"Naymagon","year":"2021","journal-title":"Acta Haematol"},{"issue":"7","key":"2023120815061669100_hem2023000463C20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood.2021012764","article-title":"An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis","volume":"139","author":"Zoref-Lorenz","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2023120815061669100_hem2023000463C21","doi-asserted-by":"crossref","first-page":"e27929","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2023120815061669100_hem2023000463C22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s10875-017-0443-1","article-title":"Effective immunological guidance of genetic analyses including exome sequencing in patients evaluated for hemophagocytic lymphohistiocytosis","volume":"37","author":"Ammann","year":"2017","journal-title":"J Clin Immunol"},{"issue":"13","key":"2023120815061669100_hem2023000463C23","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2023120815061669100_hem2023000463C24","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2023120815061669100_hem2023000463C25","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"2023120815061669100_hem2023000463C26","doi-asserted-by":"crossref","first-page":"e28581","DOI":"10.1002\/pbc.28581","article-title":"The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis","volume":"67","author":"Bami","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2023120815061669100_hem2023000463C27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/blood.2019001333","article-title":"Calming the storm in HLH","volume":"134","author":"Zinter","year":"2019","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/31\/2175628\/31kumar.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/31\/2175628\/31kumar.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:10:12Z","timestamp":1702048212000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/31\/506425\/Inflamed-HLH-MAS-or-something-else"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000463","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}